


**Amendments to the Claims**

Please add new Claims 46-49. The Claim Listing below will replace all prior versions of the claims in the application:

**Claim Listing**

1. (Previously presented) A method of treating a patient suffering from or susceptible to an RSV infection, which method comprises administering to said patient an effective amount of a benzodiazepine derivative of formula (I), or a pharmaceutically acceptable salt thereof,



wherein:

- $R^1$  represents  $C_{1-6}$  alkyl, aryl or heteroaryl;
- $R^2$  represents hydrogen or  $C_{1-6}$  alkyl;
- each  $R^3$  is the same or different and represents halogen, hydroxy,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy,  $C_{1-6}$  alkylthio,  $C_{1-6}$  haloalkyl,  $C_{1-6}$  haloalkoxy, amino, mono( $C_{1-6}$  alkyl)amino, di( $C_{1-6}$  alkyl)amino, nitro, cyano,  $-CO_2R'$ ,  $-CONR'R''$ ,  $-NH-CO-R'$ ,  $-S(O)R'$ ,  $-S(O)_2R'$ ,  $-NH-S(O)_2R'$ ,  $-S(O)NR'R''$  or  $-S(O)_2NR'R''$ , wherein each  $R'$  and  $R''$  is the same or different and represents hydrogen or  $C_{1-6}$  alkyl;
- $n$  is from 0 to 3;
- $R^4$  represents hydrogen or  $C_{1-6}$  alkyl;
- $R^5$  represents  $C_{1-6}$  alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-( $C_{1-6}$  alkyl)-, heteroaryl-( $C_{1-6}$  alkyl)-, carbocyclyl-( $C_{1-6}$  alkyl)-, heterocyclyl-( $C_{1-6}$  alkyl)-, aryl-

(C<sub>1-6</sub> hydroxyalkyl)-, heteroaryl-(C<sub>1-6</sub> hydroxyalkyl)-, carbocyclyl-(C<sub>1-6</sub> hydroxyalkyl)-, heterocyclyl-(C<sub>1-6</sub> hydroxyalkyl)-, aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)-, carbocyclyl-C(O)-C(O)-, heterocyclyl-C(O)-C(O)- or -XR<sup>6</sup>;

- X represents -CO-, -S(O)- or -S(O)<sub>2</sub>-; and

- R<sup>6</sup> represents C<sub>1-6</sub> alkyl, hydroxy, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C<sub>1-6</sub> alkyl)-, heteroaryl-(C<sub>1-6</sub> alkyl)-, carbocyclyl-(C<sub>1-6</sub> alkyl)-, heterocyclyl-(C<sub>1-6</sub> alkyl)-, aryl-(C<sub>1-6</sub> alkyl)-O-, heteroaryl-(C<sub>1-6</sub> alkyl)-O-, carbocyclyl-(C<sub>1-6</sub> alkyl)-O-, heterocyclyl-(C<sub>1-6</sub> alkyl)-O- or -NR'R'' wherein each R' and R'' is the same or different and represents hydrogen, C<sub>1-6</sub> alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C<sub>1-6</sub> alkyl)-, heteroaryl-(C<sub>1-6</sub> alkyl)-, carbocyclyl-(C<sub>1-6</sub> alkyl)- or heterocyclyl-(C<sub>1-6</sub> alkyl)-.

2. (Previously presented) A method according to claim 1 wherein:

- each R<sup>3</sup> is the same or different and represents halogen, hydroxy, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> haloalkoxy, amino, mono(C<sub>1-6</sub> alkyl)amino, di(C<sub>1-6</sub> alkyl)amino, nitro, cyano, -CO<sub>2</sub>R', -CONR'R'', -NH-CO-R', -S(O)R', -S(O)<sub>2</sub>R', -NH-S(O)<sub>2</sub>R' or -S(O)NR'R'', wherein each R' and R'' is the same or different and represents hydrogen or C<sub>1-6</sub> alkyl;

- R<sup>5</sup> represents C<sub>1-6</sub> alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C<sub>1-6</sub> alkyl)-, heteroaryl-(C<sub>1-6</sub> alkyl)-, carbocyclyl-(C<sub>1-6</sub> alkyl)-, heterocyclyl-(C<sub>1-6</sub> alkyl)- or -XR<sup>6</sup>;

- X represents -CO-, -S(O)- or -S(O)<sub>2</sub>-; and


- R<sup>6</sup> represents C<sub>1-6</sub> alkyl, hydroxy, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C<sub>1-6</sub> alkyl)-, heteroaryl-(C<sub>1-6</sub> alkyl)-, carbocyclyl-(C<sub>1-6</sub> alkyl)-, heterocyclyl-(C<sub>1-6</sub> alkyl)- or -NR'R'' wherein each R' and R'' is the same or different and represents hydrogen, C<sub>1-6</sub> alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C<sub>1-6</sub> alkyl)- or heteroaryl-(C<sub>1-6</sub> alkyl)-.

3. (Previously presented) A method according to claim 1, wherein R<sup>1</sup> is C<sub>1-2</sub> alkyl or aryl.

4. (Previously presented) A method according to claim 1, wherein  $R^2$  is hydrogen.
5. (Previously presented) A method according to claim 1, wherein  $R^3$  is halogen, hydroxy,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy,  $C_{1-4}$  alkylthio,  $C_{1-4}$  haloalkyl,  $C_{1-4}$  haloalkoxy, amino, mono( $C_{1-4}$  alkyl)amino or di( $C_{1-4}$  alkyl)amino.
6. (Previously presented) A method according to claim 5, wherein  $R^3$  is fluorine, chlorine, bromine,  $C_{1-2}$  alkyl,  $C_{1-2}$  alkoxy,  $C_{1-2}$  alkylthio,  $C_{1-2}$  haloalkyl,  $C_{1-2}$  haloalkoxy, amino, mono( $C_{1-2}$  alkyl)amino or di ( $C_{1-2}$  alkyl)amino.
7. (Previously presented) A method according to claim 1, wherein  $R^4$  is hydrogen or  $C_{1-2}$  alkyl.
8. (Previously presented) A method according to claim 1, wherein  $R^5$  is  $C_{1-6}$  alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-( $C_{1-4}$  alkyl)-, heteroaryl-( $C_{1-4}$  alkyl)-, carbocyclyl-( $C_{1-4}$  alkyl)-, heterocyclyl-( $C_{1-4}$  alkyl)-, aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)- or -XR<sup>6</sup>.
9. (Previously presented) A method according to claim 8, wherein  $R^5$  is  $C_{1-4}$  alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, phenyl-( $C_{1-2}$  alkyl)-, heteroaryl-( $C_{1-2}$  alkyl)-, phenyl-C(O)-C(O)-, heteroaryl-C(O)-C(O)- or -XR<sup>6</sup>.
10. (Previously presented) A method according to claim 9, wherein  $R^5$  is  $C_{1-4}$  alkyl, phenyl, thienyl, furanyl, isoxazolyl, pyridyl, cyclopentyl, cyclohexyl, benzothienyl, dihydrobenzofuranyl, phenyl-CH<sub>2</sub>-, furanyl-CH<sub>2</sub>-, phenyl-C(O)-C(O)-, thienyl-C(O)-C(O)- or -XR<sup>6</sup>.
11. (Previously presented) A method according to claim 1 wherein X is -CO- or -S(O)<sub>2</sub>-.

12. (Previously presented) A method according to claim 1 wherein, when  $R^6$  is a group -  $NR'R''$  wherein each  $R'$  and  $R''$  is the same or different and represents hydrogen,  $C_{1-4}$  alkyl, aryl, carbocyclyl, heterocyclyl, aryl-( $C_{1-4}$  alkyl)- or heteroaryl-( $C_{1-4}$  alkyl)-.
13. (Previously presented) A method according to claim 12, wherein when  $R^6$  is a group -  $NR'R''$  each  $R'$  and  $R''$  is the same or different and represents hydrogen,  $C_{1-4}$  alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl- $CH_2$ -.
14. (Previously presented) A method according to claim 13, wherein when  $R^6$  is a group -  $NR'R''$  and one of  $R'$  and  $R''$  is hydrogen.
15. (Previously presented) A method according to claim 1 wherein  $R^6$  is  $C_{1-6}$  alkyl, hydroxy,  $C_{1-6}$  alkoxy,  $C_{1-6}$  alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-( $C_{1-4}$  alkyl)-, heteroaryl-( $C_{1-4}$  alkyl)-, carbocyclyl-( $C_{1-4}$  alkyl)-, heterocyclyl-( $C_{1-4}$  alkyl)-, aryl-( $C_{1-4}$  hydroxyalkyl)-, heteroaryl-( $C_{1-4}$  hydroxyalkyl)-, carbocyclyl-( $C_{1-4}$  hydroxyalkyl)-, heterocyclyl-( $C_{1-4}$  hydroxyalkyl)-, aryl-( $C_{1-4}$  alkyl)-O-, heteroaryl-( $C_{1-4}$  alkyl)-O-, carbocyclyl-( $C_{1-4}$  alkyl)-O-, heterocyclyl-( $C_{1-4}$  alkyl)-O- or - $NR'R''$ .
16. (Previously presented) A method according to claim 15, wherein  $R^6$  is  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy,  $C_{1-6}$  alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, phenyl-( $C_{1-2}$  alkyl)-, phenyl-( $C_{1-2}$  alkyl)-O-, heteroaryl-( $C_{1-2}$  alkyl)-, phenyl-( $C_{1-2}$  hydroxyalkyl)-, heteroaryl-( $C_{1-2}$  hydroxyalkyl)- or - $NR'R''$ .
17. (Previously presented) A method according to claim 16, wherein  $R^6$  is  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy, phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H-fluoren-9-onyl, indolyl, thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl, benzofuranyl, cyclopentyl, cyclohexyl, piperazinyl, piperidinyl, morpholinyl, phenyl-( $C_{1-2}$  alkyl)-, phenyl- $CH_2$ -CH(OH)-, phenyl-CH(OH)- $CH_2$ -, phenyl-( $C_{1-2}$  alkyl)-O-, 1H-benzo[d]imidazol-2(3H)-onyl or - $NR'R''$ .

18. (Previously presented) A method according to claim 1, wherein the benzodiazepine derivative of formula (I) is a benzodiazepine derivative of formula (Ia):



wherein:

- R<sup>1</sup> is phenyl or methyl;
- R<sup>3</sup> is methyl or chlorine;
- n is 0 or 1;
- R<sup>4</sup> is hydrogen or methyl;
- R<sup>5</sup> is phenyl-CH<sub>2</sub>-, furanyl-CH<sub>2</sub>-, thienyl-C(O)-C(O)- or -XR<sup>6</sup>;
- X is -CO- or -S(O)<sub>2</sub>-; and
- R<sup>6</sup> is C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H-fluoren-9-onyl, indolyl, thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl, benzofuranyl, cyclopentyl, cyclohexyl, piperazinyl, piperidiny, morpholinyl, phenyl-(C<sub>1-2</sub> alkyl)-, phenyl-CH<sub>2</sub>-CH(OH)-, phenyl-CH(OH)-CH<sub>2</sub>-, phenyl-(C<sub>1-2</sub> alkyl)-O-, 1*H*-benzo[*d*]imidazol-2(3*H*)-onyl or -NR'<sup>6</sup>R'' wherein each R' and R'' is the same or different and represents hydrogen, C<sub>1-4</sub> alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl-(CH<sub>2</sub>)-,

the phenyl moiety in the group R<sup>1</sup> being unsubstituted or substituted by a single fluorine, chlorine, C<sub>1-2</sub> alkyl, C<sub>1-2</sub> alkoxy, C<sub>1-2</sub> alkylthio, C<sub>1-2</sub> haloalkyl or C<sub>1-2</sub> haloalkoxy substituent;

the aryl moieties in the groups R<sup>5</sup> and R<sup>6</sup> being unsubstituted or substituted by 1,2 or 3 substituents selected from fluorine, chlorine, bromine, iodine, C<sub>1-4</sub> alkyl, C<sub>2-4</sub> acyl, hydroxy, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkylthio, C<sub>1-4</sub> haloalkyl, C<sub>1-4</sub> haloalkoxy, amino, mono(C<sub>1-4</sub>


alkyl)amino, di(C<sub>1-4</sub> alkyl)amino, nitro, -CO<sub>2</sub>R', -S(O)<sub>2</sub>R' and -S(O)<sub>2</sub>NH<sub>2</sub>, wherein R' represents C<sub>1-2</sub> alkyl;

the heteroaryl moieties in the groups R<sup>5</sup> and R<sup>6</sup> being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, C<sub>1-2</sub> alkyl, C<sub>1-2</sub> haloalkyl and di(C<sub>1-2</sub> alkyl)amino; and

the heterocyclyl and carbocyclyl moieties in the R<sup>6</sup> group being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> haloalkyl and nitro.

19. (Previously presented) A method according to claim 1, wherein the patient is a child under two years of age.
20. (Previously presented) A method according to claim 19 wherein said child suffers from chronic lung disease.
21. (Previously presented) A method according to claim 1 wherein the patient is an infant less than six years of age who was born after 32 weeks of gestation or less.
22. (Previously presented) A method according to claim 1, wherein the benzodiazepine derivative or salt thereof is administered intranasally or intrabronchially.
23. (Previously presented) A method according to claim 1, wherein an anti-inflammatory compound or an anti-influenza compound is further administered to the patient.
24. (Previously presented) A method according to claim 23 wherein the anti-inflammatory compound is budesonide or fluticasone.
25. (Previously presented) A method according to claim 23 wherein the anti-inflammatory compound is a leukotriene antagonist, phosphodiesterase 4 inhibitor or TNF alpha inhibitor.

26. (Previously presented) A method according to claim 23 wherein the anti-inflammatory compound is an interleukin 8 or interleukin 9 inhibitor.
- 27-30. (Canceled)
31. (Previously presented) An inhaler or nebuliser containing a medicament which comprises
- (a) a benzodiazepine derivative of formula (I), as defined in claim 1, or a pharmaceutically acceptable salt thereof, and
  - (b) a pharmaceutically acceptable carrier or diluent.
32. (Previously presented) A product comprising a compound of formula (I), or pharmaceutically acceptable salt thereof, as defined in claim 1, and an anti-inflammatory compound, or an anti-influenza compound.
33. (Previously presented) A method of treating a patient suffering from or susceptible to concomitant RSV and influenza infections, which method comprises administering to said patient an effective amount of a product according to claim 32.
34. (Previously presented) A method of treating a patient suffering from or susceptible to human metapneumovirus, measles, parainfluenza viruses, mumps, yellow fever virus (B5 strain), Dengue 2 virus or West Nile virus, which method comprises administering to said patient an effective amount of a compound of formula (I), as defined in claim 1, or a pharmaceutically acceptable salt thereof.
35. (Original) A benzodiazepine derivative of formula (Ib), or a pharmaceutically acceptable salt thereof



wherein:

- $R^1$  represents  $C_{1-6}$  alkyl, aryl or heteroaryl;
- $R^2$  represents hydrogen,  $C_{1-6}$  alkyl;
- each  $R^3$  is the same or different and represents halogen, hydroxy,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy,  $C_{1-6}$  alkylthio,  $C_{1-6}$  haloalkyl,  $C_{1-6}$  haloalkoxy, amino, mono( $C_{1-6}$  alkyl)amino, di( $C_{1-6}$  alkyl)amino, nitro, cyano,  $-CO_2R'$ ,  $-CONR'R''$ ,  $-NH-CO-R'$ ,  $-S(O)R'$ ,  $-S(O)_2R'$ ,  $-NH-S(O)_2R'$ ,  $-S(O)NR'R''$  or  $-S(O)_2NR'R''$ , wherein each  $R'$  and  $R''$  is the same or different and represents hydrogen or  $C_{1-6}$  alkyl;
- $n$  is from 0 to 3;
- $R^4$  represents hydrogen or  $C_{1-6}$  alkyl;
- $R^5$  represents  $C_{3-6}$  alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-( $C_{1-6}$  alkyl)-, heteroaryl-( $C_{1-6}$  alkyl)-, carbocyclyl-( $C_{1-6}$  alkyl)-, heterocyclyl-( $C_{1-6}$  alkyl)-, aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)-, carbocyclyl-C(O)-C(O)-, heterocyclyl-C(O)-C(O)- or  $-X'$ , provided that when  $R^5$  is heteroaryl it is not 2-quinaldyl or 6-chloro-pyrazinyl, when  $R^5$  is heteroaryl-( $C_{1-6}$  alkyl)- it is not 2-indolylmethyl, 2-(3-indolyl)ethyl or 2-furanylmethyl, when  $R^5$  is aryl it is not unsubstituted phenyl and when  $R^5$  is aryl-( $C_{1-6}$  alkyl)- it is not unsubstituted phenyl-( $C_{1-2}$  alkyl)- or 4-chlorophenyl-( $C_{2-3}$  alkyl)-;
- $X'$  represents  $-CO-R^{6'}$ ,  $-S(O)-R^{6''}$  or  $-S(O)_2-R^{6'''}$ ;
- $R^{6'}$  represents  $C_1$  alkyl, hydroxy,  $C_{1-6}$  alkoxy,  $C_{1-6}$  alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-( $C_{1-6}$  alkyl)-, heteroaryl-( $C_{1-6}$  alkyl)-, carbocyclyl-( $C_{1-6}$  alkyl)-, heterocyclyl-( $C_{1-6}$  alkyl)-, aryl-( $C_{1-6}$  alkyl)-O-, heteroaryl-( $C_{1-6}$  alkyl)-O-, carbocyclyl-( $C_{1-6}$  alkyl)-O-, heterocyclyl-( $C_{1-6}$  alkyl)-O- or  $-NR'R''$  wherein each  $R'$  and  $R''$  is the same or different and represents hydrogen,  $C_{1-6}$  alkyl, carbocyclyl, heterocyclyl,

aryl, heteroaryl, aryl-(C<sub>1-6</sub> alkyl)-, heteroaryl-(C<sub>1-6</sub> alkyl)-, carbocyclyl-(C<sub>1-6</sub> alkyl)- or heterocyclyl-(C<sub>1-6</sub> alkyl)-, provided that (a) when R<sup>6'</sup> is aryl it is not unsubstituted naphthyl, unsubstituted phenyl, mono-halophenyl, 4-methylphenyl, 4-methoxyphenyl, 4-hydroxyphenyl, 4-trifluoromethylphenyl, 4-nitrophenyl, 4-cyanophenyl, 4-*n*-propylphenyl, 4-*t*-butylphenyl, 4-*n*-pentylphenyl, 4-dimethylaminophenyl, 4-methylthiophenyl, 3-trifluoromethylthiophenyl, 3,4-dimethoxyphenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2,3,4,5,6-pentafluorophenyl, 4-chloro-2-aminophenyl or 4-1,1-dimethylethylphenyl, (b) when R<sup>6'</sup> is heteroaryl it is not 2-pyrrolyl, 2-pyrazinyl, 2-quinaldyl, 2-quinoxaliny, 1-methylindolyl, 2-methyl-indolyl, 2-benzofuranyl, 2-benzothienyl, 3-thienyl, 3-indolyl, unsubstituted 2-indolyl, 5-fluoroindol-2-yl, 5-chloroindol-2-yl, 5-bromoindol-2-yl, 5-hydroxyindol-2-yl or 5-methoxyindol-2-yl, (c) when R<sup>6'</sup> is aryl-(C<sub>1-6</sub> alkyl)- it is not 4-thianaphthene-(CH<sub>2</sub>)-, unsubstituted phenyl-(CH<sub>2</sub>)-, 4-trifluoromethylphenyl-(CH<sub>2</sub>)-, unsubstituted phenyl-(CH<sub>2</sub>)<sub>3</sub>-, monotrifluoromethylphenyl-(CH<sub>2</sub>)<sub>2</sub>-, 3-methoxyphenyl-(CH<sub>2</sub>)<sub>2</sub>-, 4-chloro-2-aminophenyl-(CH<sub>2</sub>)<sub>2</sub>-, 2,4-dichlorophenyl-(CH<sub>2</sub>)<sub>2</sub>-, monochlorophenyl-(CH<sub>2</sub>)<sub>2</sub>-, 2,4-trifluoromethyl phenyl-(CH<sub>2</sub>)<sub>2</sub>-, 4-cyanophenyl-(CH<sub>2</sub>)<sub>2</sub>- or 3-cyanophenyl-(CH<sub>2</sub>)<sub>2</sub>-, (d) when R<sup>6'</sup> is heteroaryl-(C<sub>1-6</sub> alkyl)- it is not indolyl-(CH<sub>2</sub>)<sub>x</sub>-, wherein x is 1, 2, 3, unsubstituted furanyl-(CH<sub>2</sub>)<sub>2</sub>-, unsubstituted thienyl-(CH<sub>2</sub>)<sub>3</sub>- (e) when R<sup>6'</sup> is carbocyclyl it is not cyclohexyl, (f) when R<sup>6'</sup> is carbocyclyl-(C<sub>1-6</sub> alkyl)- it is not unsubstituted cyclohexyl-(CH<sub>2</sub>)<sub>1,3</sub>-, (g) when R<sup>6'</sup> is heterocyclyl it is not N-pyrrolidinyl or 2-dihydrobenzofuranyl, (h) when R<sup>6'</sup> is aryl-(C<sub>1-6</sub> alkyl)-O- it is not unsubstituted phenyl-(CH<sub>2</sub>)-O-, and (i) when R' is hydrogen, R'' is not unsubstituted phenyl, 4-halophenyl, 3-halophenyl, methoxyphenyl, nitrophenyl, 2-chlorophenyl, 4-methylphenyl, dichlorophenyl, 3,5-dimethylphenyl, 3-methylphenyl, 3-cyanophenyl, 3-aminophenyl, 3-aminocarbonylphenyl, 3-benzoic acid, 3-benzoic acid ethyl ester, 6-amino-3-pyridyl, 5-(2-chloro)pyridyl, 5-(2-methoxy)pyridyl, 5-indanyl, unsubstituted cyclohexyl, 1,1-dimethylethyl, unsubstituted phenyl-CH<sub>2</sub>-, unsubstituted naphthyl or benzotriazol-3-yl and when R' is methyl, R'' is not cyclopropylbenzene;

- R<sup>6''</sup> represents C<sub>1-6</sub> alkyl, hydroxy, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C<sub>1-6</sub> alkyl)-, heteroaryl-(C<sub>1-6</sub> alkyl)-, carbocyclyl-(C<sub>1-6</sub>

alkyl)-, heterocyclyl-(C<sub>1-6</sub> alkyl)-, aryl-(C<sub>1-6</sub> alkyl)-O-, heteroaryl-(C<sub>1-6</sub> alkyl)-O-, carbocyclyl-(C<sub>1-6</sub> alkyl)-O-, heterocyclyl-(C<sub>1-6</sub> alkyl)-O- or -NR'<sup>6</sup>R'' wherein each R' and R'' is the same or different and represents hydrogen, C<sub>1-6</sub> alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C<sub>1-6</sub> alkyl)-, heteroaryl-(C<sub>1-6</sub> alkyl)-, carbocyclyl-(C<sub>1-6</sub> alkyl)- or heterocyclyl-(C<sub>1-6</sub> alkyl)-; and

- R<sup>6'''</sup> represents C<sub>1-6</sub> alkyl, hydroxy, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C<sub>1-6</sub> alkyl)-, heteroaryl-(C<sub>1-6</sub> alkyl)-, carbocyclyl-(C<sub>1-6</sub> alkyl)-, heterocyclyl-(C<sub>1-6</sub> alkyl)-, aryl-(C<sub>1-6</sub> alkyl)-O-, heteroaryl-(C<sub>1-6</sub> alkyl)-O-, carbocyclyl-(C<sub>1-6</sub> alkyl)-O-, heterocyclyl-(C<sub>1-6</sub> alkyl)-O- or -NR'<sup>6</sup>R'' wherein each R' and R'' is the same or different and represents hydrogen, C<sub>1-6</sub> alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C<sub>1-6</sub> alkyl)-, heteroaryl-(C<sub>1-6</sub> alkyl)-, carbocyclyl-(C<sub>1-6</sub> alkyl)- or heterocyclyl-(C<sub>1-6</sub> alkyl)-, provided that when R<sup>6'''</sup> is aryl it is not 4-methylphenyl, provided that the compound of formula (Ib) is not N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-acetamide.

36. (Original) A benzodiazepine derivative according to claim 35 wherein:

- R<sup>5'</sup> is C<sub>3-6</sub> alkyl, C<sub>3-6</sub> cycloalkyl, heterocyclyl, C<sub>3-6</sub> cycloalkyl-(C<sub>1-6</sub> alkyl), aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)-, carbocyclyl-C(O)-C(O)-, heterocyclyl-C(O)-C(O)- or -X';


- X' is -CO-R<sup>6'</sup>, -S(O)-R<sup>6''</sup> or -S(O)<sub>2</sub>-R<sup>6'''</sup>;

- R<sup>6'</sup> is C<sub>1</sub> alkyl, hydroxy, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, heterocyclyl-(C<sub>1-6</sub> alkyl)-, heteroaryl-(C<sub>1-6</sub> alkyl)-O-, carbocyclyl-(C<sub>1-6</sub> alkyl)-O-, heterocyclyl-(C<sub>1-6</sub> alkyl)-O- or -NR'<sup>6</sup>R'' wherein each R' and R'' is the same or different and represents hydrogen, C<sub>1-6</sub> alkyl, C<sub>3-6</sub> cycloalkyl, heterocyclyl, carbocyclyl-(C<sub>1-6</sub> alkyl)- or heterocyclyl-(C<sub>1-6</sub> alkyl)-;

- R<sup>6''</sup> represents C<sub>1-6</sub> alkyl, hydroxy, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C<sub>1-6</sub> alkyl)-, heteroaryl-(C<sub>1-6</sub> alkyl)-, carbocyclyl-(C<sub>1-6</sub> alkyl)-, heterocyclyl-(C<sub>1-6</sub> alkyl)-, aryl-(C<sub>1-6</sub> alkyl)-O-, heteroaryl-(C<sub>1-6</sub> alkyl)-O-, carbocyclyl-(C<sub>1-6</sub> alkyl)-O-, heterocyclyl-(C<sub>1-6</sub> alkyl)-O- or -NR'<sup>6</sup>R'' wherein each R' and R'' is the same or different and represents hydrogen, C<sub>1-3</sub> alkyl, heterocyclyl, heteroaryl, heteroaryl-(C<sub>1-6</sub> alkyl)-, carbocyclyl-(C<sub>1-6</sub> alkyl)- or heterocyclyl-(C<sub>1-6</sub> alkyl)-; and

-  $R^{6///}$  is  $C_{1-6}$  alkyl, hydroxy,  $C_{1-6}$  alkoxy,  $C_{1-6}$  alkylthio,  $C_{3-6}$  cycloalkyl, heterocyclyl,  $C_{3-6}$  cycloalkyl- $(C_{1-6}$  alkyl)-, heterocyclyl- $(C_{1-6}$  alkyl)-, aryl- $(C_{1-6}$  alkyl)-O-, heteroaryl- $(C_{1-6}$  alkyl)-O-, carbocyclyl- $(C_{1-6}$  alkyl)-O-, heterocyclyl- $(C_{1-6}$  alkyl)-O- or - $NR'R''$  wherein each  $R'$  and  $R''$  is the same or different and represents hydrogen,  $C_{1-6}$  alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl- $(C_{1-6}$  alkyl)-, heteroaryl- $(C_{1-6}$  alkyl), carbocyclyl- $(C_{1-6}$  alkyl)- or heterocyclyl- $(C_{1-6}$  alkyl)-.

37. (Previously presented) A benzodiazepine derivative according to claim 35 wherein  $R^2$  is hydrogen.
38. (Original) A benzodiazepine derivative of formula (Ic), or a pharmaceutically acceptable salt thereof,



wherein:

- $R^1$  is phenyl or methyl;
- $R^3$  is methyl or chlorine;
- $n$  is 0 or 1;
- $R^4$  is hydrogen or methyl;
- $R^5$  is phenyl- $CH_2$ - thienyl- $C(O)-C(O)-$  or  $-X'$ ;
- $X'$  is  $-CO-R^6$ ,  $-CONR'R''$ ,  $-S(O)_2R^{6///}$  or  $-S(O)_2-NR/R''$ ; and
- $R^6$  is  $C_1$  alkyl,  $C_{1-4}$  alkoxy, benzodioxinyl, 9H-fluoren-9-onyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, cyclopentyl, piperazinyl, piperidinyl, morpholinyl, phenyl- $CH_2-CH(OH)-$ , phenyl- $CH(OH)-CH_2-$ , phenyl- $(C_2$  alkyl)-O- or 1*H*-benzo[*d*]imidazol-2(3*H*)-only;

- $R^{6'''}$  is  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy, phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H-fluoren-9-onyl, indolyl, thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl, benzofuranyl, cyclopentyl, cyclohexyl, piperazinyl, piperidiny, morpholinyl, phenyl- $(C_{1-2}$  alkyl)-, phenyl- $CH_2-CH(OH)-$ , phenyl- $CH(OH)-CH_2-$ , phenyl- $(C_{1-2}$  alkyl)-O- or 1*H*-benzo[*d*]imidazol-2(3*H*)-only;
- each  $R'$  and  $R''$  is the same or different and represents hydrogen,  $C_{1-4}$  alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl- $(CH_2)-$ ; and
- each  $R_i$  and  $R_{ii}$  is the same or different and represents hydrogen,  $C_{1-4}$  alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl- $(CH_2)-$ , wherein:

the phenyl moiety in the group  $R^1$  being unsubstituted or substituted by a single fluorine, chlorine,  $C_{1-2}$  alkyl,  $C_{1-2}$  alkoxy,  $C_{1-2}$  alkylthio,  $C_{1-2}$  haloalkyl or  $C_{1-2}$  haloalkoxy substituent;

the aryl moieties in the groups  $R^{5'}$ ,  $R^{6'}$  and  $R^{6'''}$  being unsubstituted or substituted by 1,2 or 3 substituents selected from fluorine, chlorine, bromine, iodine,  $C_{1-4}$  alkyl,  $C_{2-4}$  acyl, hydroxy,  $C_{1-4}$  alkoxy,  $C_{1-4}$  alkylthio,  $C_{1-6}$  haloalkyl,  $C_{1-4}$  haloalkoxy, amino, mono( $C_{1-4}$  alkyl)amino, di( $C_{1-4}$  alkyl)amino, nitro,  $-CO_2R'$ ,  $-S(O)_2R'$  and  $-S(O)_2NH_2$ , wherein  $R'$  represents  $C_{1-2}$  alkyl;

the heteroaryl moieties in the groups  $R^{5'}$ ,  $R^{6'}$  and  $R^{6'''}$  being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine,  $C_{1-2}$  alkyl,  $C_{1-2}$  haloalkyl and di( $C_{1-2}$  alkyl)amino;


the heterocyclyl and carbocyclyl moieties in the  $R^{6'''}$  group being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy,  $C_{1-4}$  haloalkyl and nitro;

the aryl, heteroaryl and carbocyclyl moieties in the  $R'$  and  $R''$  being unsubstituted or substituted by one or two substituents selected from fluorine, chlorine, bromine,  $C_{1-2}$  alkyl,  $C_{1-2}$  alkoxy,  $C_{1-2}$  alkylthio,  $C_{1-2}$  haloalkyl and nitro; and

the aryl, heteroaryl and carbocyclyl moieties in the  $R_i$  and  $R_{ii}$  being unsubstituted or substituted by one or two substituents selected from fluorine, chlorine, bromine,  $C_{1-2}$  alkyl,  $C_{1-2}$  alkoxy,  $C_{1-2}$  alkylthio,  $C_{1-2}$  haloalkyl and nitro,


provided that the compound of formula (Ic) is not N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-acetamide.

39. (Original) A benzodiazepine derivative of formula (Id), or pharmaceutically acceptable salts thereof



wherein  $R^{6*}$  is an aryl group which is unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen,  $C_{1-6}$  alkyl,  $C_{2-7}$  acyl, hydroxy,  $C_{1-6}$  alkoxy,  $C_{1-6}$  alkylthio,  $C_{1-6}$  haloalkyl,  $C_{1-6}$  haloalkoxy, nitro, cyano, carbamoyl, mono( $C_{1-6}$  alkyl)carbamoyl, di( $C_{1-6}$  alkyl)carbamoyl, amino, mono( $C_{1-6}$  alkyl)amino, di( $C_{1-6}$  alkyl)amino,  $-CO_2R'$ ,  $-CONR'R''$ ,  $-S(O)R'$ ,  $-S(O)_2R'$ ,  $-S(O)NR'R''$ ,  $-S(O)_2NR'R''$ ,  $-NH-S(O)_2R'$  or  $-NH-CO-R'$ , wherein each  $R'$  and  $R''$  is the same or different and represents hydrogen or  $C_{1-6}$  alkyl, provided that  $R^{6*}$  is not a 4-chlorophenyl group.

40. (Original) A benzodiazepine derivative of formula (Ie) or a pharmaceutically acceptable salts thereof



wherein R'\* is an aryl group which is unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkylthio, C<sub>1-4</sub> haloalkyl, C<sub>1-4</sub> haloalkoxy and nitro.

41. (Original) 1,1-Diethyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea  
 N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionamide  
 N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-butyramide  
 N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-isobutyramide  
 2,2-Dimethyl-N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionamide  
 Cyclopentanecarboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide  
 Cyclohexanecarboxylic acid 2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide  
 Piperidine-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide  
 Morpholine-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide  
 4-Methyl-piperazine-1-carboxylic acid -(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide  
 Benzo[b]thiophene-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide  
 Isoxazole-5-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide  
 Benzo[b]thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide  
 N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-methanesulfonamide

Propane-1-sulfonic acid-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

Butane-1-sulfonic acid-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-isobutyramide

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-isonicotinamide

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide

N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-acetamide

(S)-2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

(S)-1-(2-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea

2-Chloro-4-methanesulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

1-(4-Nitro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea

4-Methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

2-Methoxy-4-methylsulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

4-Methanesulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)terephthalamide acid methyl ester

5-Acetyl-2-ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

3-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-terephthalamide acid methyl ester

2-Methylsulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

4-Amino-5-chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

4-Methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

(S)-2,4,5-Trifluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

(S)-5-Acetyl-2-ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

2-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-5-sulfamoylbenzamide

1-tert-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea

1-Cycloheptyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea

1-Ethyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea

1-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea

4,5-Dimethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide

Piperidine-1-carboxylic acid (7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide

N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-isobutyramide

Cyclohexanecarboxylic acid [5-(3-chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide

Piperidine-1-carboxylic acid [5-(3-chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide

N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]isonicotinamide

N-[5-(3-Methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-isobutyramide

Cyclohexanecarboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide

Piperidine-1-carboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide

Piperidine-4-carboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide

Cyclohexanecarboxylic acid (8-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

6-Morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide

Pyridine-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

6-Fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

1H-Pyrazole-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

6-Dimethylamino-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide

2-Ethoxy-naphthalene-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

9-Oxo-9H-fluorene-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

2-Oxo-2,3-dihydro-benzimidazole-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid tert-butyl ester

(S)-6-Fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

(S)-4,5-Dibromo-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

(S)-3-Methoxy-naphthalene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide  
(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid methyl ester  
(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid ethyl ester  
(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid isobutyl ester  
2-Oxo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-thiophene-2-yl-acetamide,  
or a pharmaceutically acceptable salt thereof.

42. (Canceled)
43. (Previously presented) A pharmaceutical composition comprising a benzodiazepine derivative according to Claim 31, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluant or carrier.
44. (Previously presented) A composition comprising an optically active isomer of a benzodiazepine derivative according to Claim 31.
45. (Previously presented) A composition according to claim 43 which is in the form of a tablet, troche, lozenge, aqueous or oily suspension, dispersible powders or granules.
46. (New) A process for preparing a benzodiazepine derivative of the formula (I), as defined in claim 1, or a pharmaceutically acceptable salt thereof, which process comprises:
  - (a) reacting 2-amino-benzophenone with bromoacetyl bromide, or an equivalent reagent, followed by ring closure with ammonia;
  - (b) protecting the NH group on the thus obtained compound by reacting with a base and an alkylating agent;
  - (c) reacting the protected intermediate thereby obtained with a base in a suitable solvent, to obtain thereby an oxime intermediate;

- (d) converting the thus obtained oxime intermediate into a corresponding racemic primary amine;
  - (e) carrying out dynamic kinetic resolution on the racemic amine in the presence of a suitable optically active acid and a suitable aldehyde to precipitate a salt of the (S)-amine.
47. (New) A process according to claim 46, which further comprises:
- (f) transforming the optically active amine obtained in step (e) into an amide or urea.
48. (New) A process according to claim 46 wherein the protecting group introduced in step (b) is 4-methoxy-benzyl.
49. (New) A process according to claim 46, wherein the benzodiazepine derivative of the formula (I) is (S)-1-(2-fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea or (S)-4-methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide.